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Purpose: Dry eye disease is highly prevalent world-
wide, causing discomfort and visual disturbances that
can limit basic activities such as reading and driving.
Although artiﬁcial tears represent ﬁrst-line therapy,
there is a paucity of published controlled clinical trials.
The present study compared the efﬁcacy, clinical
safety, and acceptability of 2 multicomponent, lipid-
based tear formulations (ADV1 and ADV2) to those
of an existing lipid-based tear formulation (DET) in
patients with signs and symptoms of dry eye disease.
Methods: This 3-month, multicenter, double-
masked study was conducted in patients with dry
eye symptoms, reduced tear break-up time (TBUT),
and ocular surface damage. Patients were randomized
to receive 1 of 2 lipid-based tear formulations con-
taining carboxymethylcellulose, glycerin, polysorbate
80, and emulsiﬁed lipid (ADV1 or ADV2) or DET,
and instilled 1 to 2 drops per eye at least twice daily.
The primary end point was the mean change from
baseline in Subjective Evaluation of Symptom of
Dryness score at day 90 to determine noninferiority
of the 2 ADV formulations versus DET. Secondary
end points included Ocular Surface Disease Index
(OSDI) score, TBUT, ocular surface staining, and
tolerability.
Findings: Of 288 randomized patients, 256 com-
pleted the study. All 3 groups showed improvement in
symptoms, and the 2 lipid-based formulations were
noninferior to DET in reducing the severity of symp-
toms of dryness at 90 days. Of the 3 treatment groups,
the ADV2 group had the greatest improvements in
TBUT and OSDI. Signiﬁcant improvements in mean
tolerability scores for comfort, soothing, burning/
stinging, and discomfort were observed in the ADV2
group versus the DET group at 90 days. Treatment-
related adverse events were reported in 13 patients
(13.4%) receiving ADV1, 8 (8.4%) receiving ADV2,858and 21 (21.9%) receiving DET. Four patients (4.1%)
in the ADV1 group and 2 (2.1%) in the ADV2 group
discontinued owing to an adverse event compared
with 14 (14.6%) receiving DET.
Implications: In these patients with dry eye symp-
toms, ADV2 was an effective and relatively well-
tolerated artiﬁcial tear for ﬁrst-line therapy and should
be considered as a treatment option for dry eye,
especially in those patients who would beneﬁt from
a lipid-based formulation in addition to lubrication.
https://clinicaltrials.gov/ct2/show/NCT01010282. (Clin
Ther. 2015;37:858–868) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
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ﬁlm.INTRODUCTION
Dry eye disease is highly prevalent worldwide and is
one of the most frequent patient complaints encoun-
tered in clinical eye care.1–5 Although more common
in older adults, dry eye occurs in younger patients as
well. Dry eye can be exacerbated by work and activity
patterns that involve prolonged and demanding visual
tasks with computers, smartphones, and other devi-
ces.3 The clinical relevance of dry eye disease is
emphasized by its signiﬁcant impact on the quality
of life of affected patients. Symptoms of ocular discomfort
include dryness, burning, stinging, photophobia, foreign
body sensation, and contact lens intolerance. TheseVolume 37 Number 4
P.A. Simmons et al.symptoms may affect basic daily activities, such as
reading, driving, and working with computers.6
Dry eye disease is characterized by a change in the
quantity and/or quality of the tear ﬁlm that leads to
insufﬁcient wetting and lubrication of the exposed
ocular surface. In the case of altered lipid secretion
from the meibomian glands, dry eye also can be
caused by an increased rate of evaporation. Excessive
evaporation results in instability of the tear ﬁlm, with
subsequent desiccation and damage to the ocular
surface and related symptoms.7,8
For eye care clinicians, dry eye disease has long been
a challenging condition to address.5 Tear supple-
mentation with ocular lubricants (artiﬁcial tears) is
considered the ﬁrst-line therapy and is often the only
therapy used in mild to moderate disease.9–11 However,
the effects of many of the available products have not
been evaluated in controlled clinical trials. The majority
of artiﬁcial tear formulations contain soluble polymeric
lubricants, such as cellulose ethers, carbomers, polyvinyl
alcohols, polyvinyl pyrrolidones, and sodium hyaluro-
nate, as the therapeutic ingredients.1 Formulations have
been developed to moisten and lubricate the ocular
surface, but they may not address evaporative dry eye.
Previously published studies have reported that
castor oil has beneﬁcial properties when added to
artiﬁcial tear preparations. The major component of
castor oil, ricinoleic acid, an unsaturated omega-9
fatty acid with a hydroxyl group, allows the castor oil
to spread readily over the aqueous component of the
tear ﬁlm, reducing evaporation and increasing tear
ﬁlm stability.1,12,13 However, blurred vision and a
viscous sensation have been reported with the use of
artiﬁcial tears containing castor oil.10
Two investigational, multicomponent, lipid-con-
taining artiﬁcial tear formulations have been designed
with the aim of maintaining the efﬁcacy of the earlier
developed, lipid-based artiﬁcial tears while improving
safety, tolerability and patients’ acceptability. Both for-
mulations (ADV1 and ADV2*) contain carboxymethyl-
cellulose (CMC), which provides lubrication, and castor
oil, which retards tear evaporation, while ADV1 also
contains olive oil. In addition, these products contain
glycerin, L-carnitine, and erythritol to protect the ocular
surface from hyperosmotic stress.14 The objective of the*Trademarks: Refreshs Optive Advanced™ Lubricant Eye
Drops (United States) and Optive Plus™ (Europe) (Allergan,
Inc, Irvine, California).
April 2015present multicenter, double-masked, randomized clinical
trial was to compare the efﬁcacy, safety, tolerability, and
acceptability of the 2 new lipid-based formulations
(ADV1 and ADV2) to those of an existing lipid-based
tear formulation (DET†) in patients with signs and
symptoms of dry eye disease.
PATIENTS AND METHODS
Patients aged 18 years of age or older, with a history
of dry eye signs and symptoms for a minimum of 3
months, were enrolled at 1 of 13 sites in the United
States. Inclusion and exclusion criteria were designed
for enrolling primarily patients with mild to moderate
dry eye in whom monotherapy with an artiﬁcial tear
would be considered appropriate by most clinicians.
Criteria included a minimum score of 2 on the Sub-
jective Evaluation of Symptom of Dryness question-
naire,15 3 consecutive measures of tear break-up time
(TBUT) o10 seconds, and ocular surface staining
observed in at least 1 zone of the cornea (with
ﬂuorescein) or conjunctiva (with Lissamine Green
[Rose Stone Enterprises, Alta Loma, California]),
using a modiﬁed National Eye Institute grading
scheme.16,17 Patients were excluded if they were
contact lens wearers; using other ophthalmic medica-
tions; and had a recent change in use of a systemic
medication, or a history of ophthalmic surgery within
1 year, or signs of severe dry eye including a Schirmer
test result of r2 mm/5 min or grade 5 staining in any
zone of the cornea or conjunctiva.
The trial was conducted in compliance with the
Declaration of Helsinki and the Health Insurance
Portability and Accountability Act. Institutional review
board approval was obtained at each investigational
site, and informed consent was obtained from each
patient before data collection. The trial is registered at
https://clinicaltrials.gov/ct2/show/NCT01010282.
Study Treatments
Using a computer algorithm, patients were
randomized, within each site on a 1:1:1 basis, to
receive 1 of 2 artiﬁcial tear formulations—ADV1 or
ADV2—or DET (Table I). Masked treatment was
allocated to the patients by an automated system and
dispensed to patients on days 1 (baseline), 30, and 60.
Patients were instructed to instill 1 to 2 study†Trademark: Refresh Dry Eye Therapys Lubricant Eye Drops
(Allergan, Inc).
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Table I. Ingredients of artificial tear formulations.*
Ingredient ADV 1† ADV 2‡ DET§
Primary lubricant
(active ingredient)
Carboxymethylcellulose
0.5%
Carboxymethylcellulose
0.5%
–
Secondary lubricant
(active ingredient)
Glycerin 1.0% Glycerin 1.0% Glycerin 1.0%
Secondary lubricant
and lipid stabilizer
(active ingredient)
Polysorbate 80 0.5% Polysorbate 80 0.5% Polysorbate 80 1.0%
Lipid Castor oil, olive oil Castor oil Castor oil
Polymeric lipid
stabilizer
Carbomer copolymer
type A
Carbomer copolymer
type A
Carbomer copolymer
type A
Osmoprotectants Levocarnitine, erythritol Levocarnitine, erythritol –
Other ingredients Boric acid (buffer),
Purites (preservative),
puriﬁed water
Boric acid (buffer),
Purites (preservative),
puriﬁed water
Mannitol (tonicity agent),
boric acid (buffer),
Purites (preservative),
puriﬁed water
*The exact concentrations of the inactive ingredients are proprietary, although the total amount of lipid in DET is 5-fold
that in ADV1 or ADV2.
†Test formulation 1.
‡Test formulation 2; trademark: Refreshs Optive Advanced™ Lubricant Eye Drops (Allergan, Inc, Irvine, California).
§Reference formulation; trademark: Refresh Dry Eye Therapys Lubricant Eye Drops (Allergan, Inc).
Clinical Therapeuticstreatment eye drops in each eye, as needed, but at least
twice daily for the entire 90-day study.
Outcome Measures
Subjective Evaluation of Symptom of Dryness
Study visits were scheduled for days 1 (baseline
assessment), 7, 30, 60, and 90 after randomization to
treatment. The primary efﬁcacy end point was the mean
change from baseline in Subjective Evaluation of Symp-
tom of Dryness score at day 90. Severity of dryness
(deﬁned as discomfort or irritation due to a dry feeling
in the eye) during the week preceding the study visit was
rated by each patient on a scale ranging from 0 (no
symptoms) to 4 (severe symptoms).15 Change from
baseline was deﬁned as the follow-up dryness score
minus the baseline dryness score, with a negative value
indicating decreased dryness, or improvement.
Ocular Surface Disease Index
Secondary efﬁcacy end points included the
Ocular Surface Disease Index (OSDI).18 The OSDI
score ranges from 0 (no disease) to 100 (severe860symptoms and complete disability), so that negative
changes from baseline indicate improvement.
Tear Break-up Time
TBUT was measured in seconds with ﬂuorescein
(mean of 3 consecutive measurements).
Tolerability Questionnaire
Treatment tolerability (4 positive questions covering
ocular comfort, soothing, moistening/lubricating, and
visual clarity, and 4 negative questions covering sensa-
tions of ocular stickiness, blurring, burning/stinging,
and discomfort) was scored on a visual analog scale
ranging from 0 to 100. Current comfort level (3
questions relating to overall comfort, ocular comfort,
and quality of vision at the time of the visit) also was
assessed on a visual analog scale ranging from 0 (could
not be worse) to 100 (could not be better).
Other Efficacy Assessments
Corneal staining with ﬂuorescein and conjunctival
staining with Lissamine Green were measured on aVolume 37 Number 4
‡Refresh Tears, Refresh Plus, Refresh Optive or Refresh Optive
Sensitive (Allergan, Inc, Irvine, California).
§Systane Ultra (Alcon Laboratories, Elkland, Maryland).
P.A. Simmons et al.0-to-5 scale in each of 5 corneal and 6 conjunctival
zones. Meibomian gland assessments included the num-
ber of functioning glands on the lower lid (scored from
0 [all glands expressible] to 3 [none or only 1 gland
expressible]) and the quality of secretions (scored from
0 [clear excreta or clear with small particles] to 3 [secre-
tions retain shape after expression]).19,20 The Schirmer
test measured basal tear secretion (in millimeters) over 5
minutes, with topical anesthesia.17 Near-visual acuity
with habitual correction was measured using near low-
contrast (10%) and high-contrast logarithmic visual
acuity charts for testing at 40 cm.
Acceptability Assessment
Treatment acceptability was assessed using 9 items:
(1) liking of the study eye drop, (2) duration of relief,
(3) effective relief of dryness, (4) normal eye sensation,
(5) daytime moisturization, (6) physical functioning,
(7) likelihood of purchasing the study eye drop, (8)
rapidity of normalization of vision, and (9) absence of
matting/crusting. Patients rated each item on a 5-point
scale: strongly agree, agree, neutral, disagree, or
strongly disagree. Treatment preference (5 items re-
lated to preference for study eye drop over previously
used eye drops) was also rated on a 5-point scale
ranging from strongly agree to strongly disagree.
Safety Assessment
Clinical safety was assessed by the monitoring of the
frequency of adverse events, measurement of distance
visual acuity, and biomicroscopy examination.
Data Analysis and Statistical Methods
For the primary efﬁcacy analysis, between-treatment
differences in mean change from baseline in Subjective
Evaluation of Symptom of Dryness score and 95% CIs
were estimated using a 2-way ANOVA model, with
treatment and study center as ﬁxed effects. Data from
the intent-to-treat population, which included all
randomized patients, were analyzed, and the last-
observation-carried-forward procedure was used to
impute missing data. In the secondary efﬁcacy analyses
of OSDI, TBUT, corneal and conjunctival staining,
Schirmer test, and current comfort assessment, a similar
model was used for assessing the treatment difference.
For variables requiring individual-eye assessments
(TBUT, Schirmer test, corneal and conjunctival stain-
ing), data from the eye with poorer scores at baseline
were analyzed.April 2015The safety population included patients who re-
ceived at least 1 dose of study treatment. Adverse
events were summarized and tabulated, including the
number and percentage of patients with serious
adverse events.
A minimum of 88 patients per treatment group
was required to obtain 85% power for a 1-sided
noninferiority test for a between-group difference (ie,
the noninferiority margin) of 0.5 grade in mean change
from baseline in Symptom of Dryness score at day 90.
This calculation was based on a 1-sided type I error
rate of 0.025, and the assumptions of no inherent
treatment difference and a common SD of 1.0.RESULTS
A total of 288 patients (216 women, 72 men) with a
mean age of 54.2 years who met the study criteria for
signs and symptoms of dry eye were randomized to
receive ADV1 (n ¼ 97), ADV2 (n ¼ 95), or DET (n ¼
96) and were included in the intent-to-treat and safety
populations (Figure 1). Other relevant ophthalmic his-
tory included pingueculae (22.2%), blepharitis (13.9%),
punctate keratitis (12.8%), corneal scarring (10.8%),
allergic conjunctivitis (8.7%), and meibomian gland
dysfunction (.6%); Sjögren syndrome was reported in
2 patients (0.7%). All patients had been using an
artiﬁcial tear for at least 3 months before study entry,
most commonly Refresh Tears‡ or Refresh Plus‡
(20.5%), Systane Ultra§ (17.7%), or Refresh Optive‡ or
Refresh Optive Sensitive‡ (12.5%). Meibomian gland
evaluation at baseline suggested that 28.1% of patients
had less than half of visible glands able to express
secretions, and 42.4% of the patients had substantially
thickened secretions or were unable to express secretions
from the meibomian glands.
In all, 256 patients completed the study. There were
no statistically signiﬁcant differences between the 3
treatment groups with respect to age, sex, or race.
Fewer patients in the investigational treatment groups
(ADV1, n ¼ 6; ADV2, n ¼ 7) than in the DET group
(n ¼ 19) exited the study early. All but 3 patients used
their study eye drop product as instructed, with a
median reported use of 2 to 3 times per day in all 3
groups.861
Enrolled
Randomized (ITT)a
91 (93.8%) 77 (80.2%)Completed study
6 total
Screened 336 48 screen failures
288
7 total 19 total
88 (92.6%)
Discontinuations
and reasons
ADV1
97
ADV2
95
DET
96
14 adverse event
1 protocol violation
2 lost to follow-up
1 lack of efficacy
1 other
2 adverse event
2 protocol violation
3 personal reasons 
4 adverse event
2 protocol violation
Figure 1. Patient flow. aIncludes all safety patients who received at least 1 dose of study treatment. See Table I
for treatment and formulation information. ITT ¼ intent-to-treatpopulation.
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Figure 2. Mean (SEM) Subjective Evaluation of
Symptom of Dryness scores at each
visit (intent-to-treat population).
Scale: 0 ¼ I do not have this symptom;
1 ¼ I seldom notice this symptom, and
it does not make me uncomfortable;
2 ¼ I sometimes notice this symptom, it
does make me uncomfortable, but it
does not interfere with my activities;
3 ¼ I frequently notice this symptom, it
does make me uncomfortable, and it
sometimes interferes with my activities;
and 4 ¼ I always notice this symptom,
it does make me uncomfortable, and it
usually interferes with my activities.
*P o 0.04 for ADV1 versus ADV2
and DET. See Table I for treatment
and formulation information.
Clinical TherapeuticsEfficacy
Subjective Evaluation of Symptom of Dryness
At baseline, the mean (SD) Symptom of Dryness
scores were 2.7 (0.59), 2.8 (0.67), and 2.8 (0.65) in
the ADV1, ADV2, and DET treatment groups, re-
spectively. The mean (SD) changes from baseline were
similar among the 3 treatment groups at day 90
(ADV1, 0.7 [0.89]; ADV2, 0.7 [0.90]; and DET,
0.7 [0.96]; all, P o 0.001) (Figure 2). Between-
group comparisons did not show statistically signiﬁ-
cant differences in change from baseline at day 90
(ie, ADV1 vs DET, ADV2 vs DET, and ADV1 vs ADV2).
Ocular Surface Disease Index
At baseline, the mean (SD) OSDI scores were 33.6
(20.19), 35.1 (19.18), and 37.3 (18.67) in the ADV1,
ADV2, and DET treatment groups, respectively. The
mean (SD) changes in scores at day 90 were 7.2
(19.47), 10.6 (18.43), and 9.1 (19.68) in the ADV1,
ADV2, and DET treatment groups, all of which were
statistically signiﬁcant improvements from baseline
(P o 0.001) (Figure 3). Between-group analyses did
not show any statistically signiﬁcant differences.
Tear Break-up Time
At baseline, the mean (SD) TBUT values were 4.90
(1.77), 5.04 (1.65), and 5.09 (1.78) seconds in the
ADV1, ADV2, and DET treatment groups, respec-
tively. At day 90, all 3 treatment groups showed
signiﬁcant improvements in TBUT (all, P o 0.001),
with mean (SD) changes from baseline of þ1.49862 Volume 37 Number 4
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Figure 3. Mean (SEM) Ocular Surface Disease
Index scores at each visit (intent-to-treat
population). No between-group differ-
ences were observed. See Table I for
treatment and formulation information.
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Figure 4. Mean (SEM) tear break-up times
(TBUT) at each visit (intent-to-treat
population). In each patient, data
from the eye with the shorter TBUT
of the 3 measurements at baseline
were used in the analysis. No be-
tween-group differences were ob-
served. See Table I for treatment
and formulation information.
P.A. Simmons et al.(2.96), þ2.02 (3.81), and þ1.81 (3.46) (Figure 4).
Between-group analyses did not show any statistically
signiﬁcant differences.
Tolerability
At the day-90 visit, based on the mean scores on all
8 items in the tolerability questionnaire, the ADV1
and ADV2 treatment groups had signiﬁcantly im-
proved tolerability (ie, higher scores on the 4 positive
questions and lower scores on the 4 negative ques-
tions) than did the DET group (Figure 5). Statistically
signiﬁcant differences in the scores on 4 items—
comfort (P ¼ 0.031), soothing (P ¼ 0.05), burning/
stinging (P ¼ 0.007), and discomfort (P ¼ 0.011)—
were observed in the ADV2 treatment group versus
the DET group and on burning/stinging (P ¼ 0.036) in
the ADV1 group versus the DET group. No
statistically signiﬁcant differences were observed
when ADV1 was compared with ADV2.
Other Efficacy Findings
Corneal and conjunctival staining was low in this
study population at baseline and did not show any
clinically relevant changes in any treatment group or
between-group differences throughout the study. Sim-
ilarly, no statistically signiﬁcant differences in meibo-
mian gland evaluation or Schirmer test values were
seen in any of the between-group comparisons. MostApril 2015patients in all 3 treatment groups had no change in
near visual acuity, measured both binocularly and by
worse eye, and by high and low contrast, at all visits
There were some isolated differences between groups
in 1 or more measures, but no clear trend across visits
and no differences between groups at the ﬁnal evalua-
tion (day 90).Acceptability
Comfort-level assessments demonstrated no signiﬁ-
cant change in either overall comfort or quality of vision
in any treatment group over the course of the study. The
ADV2 group had a signiﬁcantly better ocular comfort
score at day 90 versus DET (P ¼ 0.019).
For acceptability and preference questionnaires,
the majority of patients in all 3 treatment groups
reported the study eye drops to be acceptable
(ie, responses of “agree,” “strongly agree,” or
“neutral”) and generally preferable to their previ-
ously used eye drops. The distribution of patient
responses for duration of relief (P ¼ 0.031), normal
eye sensation (P ¼ 0.029), and likelihood of pur-
chase (P ¼ 0.022) was less acceptable with ADV1
compared with DET.863
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Figure 5. Tolerability scores for each question, by
visit (intent-to-treat population). Ques-
tionnaire items: (1) How comfortable
is the drop in your eye?; (2) How
soothing is the drop in your eye?; (3)
How moistening/lubricating is the drop
in your eye?; (4) How clear is your
vision with the drop in your eye?; (5)
How much stickiness do you have with
the drop in your eye?; (6) How much
blur do you have with the drop in your
eye?; (7) How much burning/stinging
do you have with the drop in your eye?;
and (8) How much discomfort do you
have with the drop in your eye? Scale:
0 ¼ “none/not at all” to 100 ¼
“much/very.” P ¼ 0.031 for comfort;
P ¼ 0.05 for soothing; P ¼ 0.007 for
burning/stinging; P ¼ 0.011 for dis-
comfort for ADV2 versus DET; P ¼
0.036 for burning/stinging for ADV1
versus DET. See Table I for treatment
and formulation information.
Clinical TherapeuticsSafety
The most frequently reported ocular adverse event
in all 3 treatment groups was visual acuity reduced,
with prevalences of 16.5%, 7.4%, and 11.5% in the
ADV1, ADV2, and DET groups, respectively. Blurred
vision was reported separately in 5.2%, 3.2%, and
7.3% of patients in the same groups (Table II).
Treatment-related adverse events were reported in 42
patients (14.6%). Overall, treatment-related adverse864events were more frequently reported in the DET group
(21.9%) compared with the ADV1 group (13.4%) or
the ADV2 group (8.4%). The most frequently rep-
orted treatment-related adverse event in all treatment
groups combined was instillation-site pain, which
occurred in 1 (1.0%) patient in the ADV1 group, 2
(2.1%) in the ADV2 group, and 8 (8.3%) in the
DET group.
Twenty (6.9%) patients discontinued the study
owing to adverse events, with the majority
(14 patients) from the DET treatment group
(Table II). Two patients (2.1%) in the ADV1
group and 4 patients (4.2%) in the DET group
reported serious adverse events that were con-
sidered by the investigator as unrelated to the
study treatment.
Distance visual acuity based on the eye with the worse
change from baseline, as well as for binocular distance
visual acuity, was unchanged (deﬁned as a change ofo2
lines in visual acuity) in 496% of the patients in each
treatment group at day 90. Biomicroscopy ﬁndings also
were reported at a low rate, with no reports of individual
biomicroscopy ﬁndings or prevalence of Z5% in any
treatment group.
DISCUSSION
The ﬁndings from the present study suggest that all 3
lipid-containing eye drop formulations evaluated
(ADV1, ADV2, and DET) reduced symptoms (Symp-
tom of Dryness and OSDI) and signs (TBUT) of dry
eye over the 90 days of treatment. Differences between
the treatment groups in tolerability, ocular comfort,
and rate of adverse events were observed, where these
data suggest that ADV2 demonstrated the best overall
performance.
These results are consistent with those from earlier
studies of lipid-containing eye drops, including stud-
ies of artiﬁcial tear formulations very similar to that
of DET. In previous reports, castor oil emulsions
similar to DET were reported to restructure the lipid
layer of the tears21,22 and to decrease tear evapora-
tion rates.13 Low-concentration castor oil eye drops
also have been reported to aid in the treatment of
meibomian gland disease while avoiding complica-
tions such as blurred vision and a viscous sensa-
tion.12 However, Sall et al23 reported that with the use
of vehicle for a cyclosporine ophthalmic emulsion,
which contains castor oil at a concentration similar
to that in DET, along with other similar ingredients,Volume 37 Number 4
Table II. Safety of artificial tear formulations. Data represent the number of patients (%).
Parameter ADV1* (n ¼ 97) ADV2* (n ¼ 95) DET* (n ¼ 96)
Patients with Z1 AE reported 45 (46.4) 34 (35.8) 45 (46.9)
Ocular AEs reported† 30 (30.9) 20 (21.1) 27 (28.1)
Visual acuity reduced 16 (16.5) 7 (7.4) 11 (11.5)
Vision blurred 5 (5.2) 3 (3.2) 7 (7.3)
Eye pain 3 (3.1) 1 (1.1) 6 (6.3)
Photophobia 3 (3.1) 1 (1.1) 5 (5.2)
Treatment-related AEs‡ 13 (13.4) 8 (8.4) 21 (21.9)
Visual acuity reduced 5 (5.2) 1 (1.1) 1 (1.0)
Vision blurred 4 (4.1) 1 (1.1) 3 (3.1)
Eye irritation 3 (3.1) 0 1 (1.0)
Eye pruritus 2 (2.1) 0 1 (1.0)
Instillation site pain 1 (1.0) 2 (2.1) 8 (8.3)
Foreign body sensation 1 (1.0) 2 (2.1) 1 (1.0)
Photophobia 1 (1.0) 0 2 (2.1)
Conjuctival hyperemia 0 0 3 (3.1)
Eye pain 0 0 3 (3.1)
Instillation site pruritus 0 0 2 (2.1)
Discontinued owing to AEs§ 4 (4.1) 2 (2.1) 14 (14.6)
Eye irritation 2 (2.1) 0 1 (1.0)
Photophobia 1 (1.0) 0 2 (2.1)
Foreign body sensation 0 2 (2.1) 1 (1.1)
Conjuctival hyperemia 0 0 2 (2.1)
Eye pain 0 0 2 (2.1)
Instillation site pain 0 0 2 (2.1)
Serious AEsǁ 2 (2.1) 0 4 (4.2)
AE ¼ adverse event.
*See Table I for treatment and formulation information.
†Ocular AEs occurring in Z5% of patients in any treatment group listed below.
‡Ocular and non-ocular treatment-related AEs occurring in Z2% of patients in any treatment group listed below.
§Ocular and non-ocular AEs resulting in discontinuation by Z2% of patients in any treatment group listed below.
ǁSerious AEs reported were abortion induced, pulmonary embolism, breast cancer, nephrolithiasis, acute myeloid leukemia
and duodenal ulcer; there were no serious ocular AEs and all reported events were considered not related to study treatment
by the investigator.
P.A. Simmons et al.the adverse-events rate was 19.5%, with reports of
side effects including blur, burning, and stinging. A
similar proﬁle was observed with DET in the present
study.
In contrast, the tolerability scores and rates of
adverse events with ADV2 were more consistent with
those that might be expected with a standard aqueous
eye drop. In a direct comparison of the lipid-
containing formula ADV2 with an aqueous-only eyeApril 2015drop, a similar reduction in dry eye symptoms was
reported, but with a greater reduction in tear ﬁlm
evaporation after 2 weeks of dosing,24 suggesting that
the formulation of ADV2, with a reduced lipid
content for improving tolerability while maintaining
the beneﬁts of the lipid, was effective. Those ﬁndings
are consistent with the results from the present study
demonstrating improvements in all groups in TBUT, a
marker of tear ﬁlm stability that may directly relate to865
Clinical Therapeuticstear evaporation. The mean improvement in TBUT at
day 90 was numerically greatest with ADV2, which
contains signiﬁcantly less lipid than does DET.
Therefore, at least with castor oil, it appears that
only a small amount needs to be added to the tear ﬁlm
to enhance the lipid layer sufﬁciently to produce
clinically meaningful beneﬁts.
An unexpected result of the present study was the
apparent trend of differences in clinical safety, toler-
ability, and acceptability between the 2 investigational
formulations, ADV1 and, ADV2. The only difference
between these 2 formulations was the substitution of
some of the castor oil with olive oil (while maintaining
the same total amount of oil) in ADV1, whereas ADV2
contains only castor oil. It is not known what charac-
teristic of the olive oil may have been associated with
the observed clinical differences; possibilities include
the fact that olive oil does not spread on aqueous
surfaces as well as does castor oil and/or that olive oil
and its potential metabolites may have a higher irritant
potential than castor oil in ophthalmic use.
All 3 study tear formulations contain glycerin, a
small molecule that rapidly enters ocular surface cells
and assists in the maintenance of normal osmotic
balance. The ADV1 and ADV2 tear formulations also
contain the osmoprotectants erythritol and levocarni-
tine, which enter cells and protects them from cellular
stress due to hyperosmolar conditions similar to those
of dry eye disease.14,25 Markers of cellular stress were
not measured in the present study, but the favorable
results observed with the 2 investigational artiﬁcial
tear formulations may have been due in part to the
presence of the additional components.
In addition to the reduced total oil and the presence
of osmoprotectants, the new tear formulations also
contain the established lubricant and demulcent
CMC, which is not a component of DET. The anionic
charge and viscosity of CMC not only provide
mucoadhesive26 and lubricating27 properties but also
have been reported to promote re-epithelialization of
corneal wounds and binding in corneal epithelial
cells.28 Although the majority of patients did not
have severe ocular surface disease, patients with
more severe dry eye could be expected to beneﬁt
from this property.
The present study was speciﬁcally designed to
include a broad spectrum of patients with dry eye,
including those with and without obvious lipid deﬁ-
ciency, and to utilize means of assessment common in866clinical practice. Thus, these results can provide
guidance to the eye care practitioner on the potential
utility of the new therapies in eye care practice.
Potential limitations of the present study include
the lack of a comparison with a more common
aqueous artiﬁcial tear formulation, and inclusion of
patients with both aqueous- and lipid-deﬁcient dry
eye. Another study focusing purely on evaporative dry
eye may be conducted to further evaluate the effective-
ness of the lipid-containing formulations. Addition-
ally, specialized clinical methods to assess beneﬁts of
the lipid-containing formulations to the tear ﬁlm lipid
layer were not performed as they are not generally
available in a standardized form for a multi-center
clinical trial.
CONCLUSIONS
The ﬁndings from the present study suggest that the
ADV2 formulation, which contains CMC for lubrica-
tion; castor oil for lipid layer stabilization; and
glycerin, erythritol, and levocarnitine for osmoprotec-
tion, was as effective as, and had better tolerability
than, the ADV1 formulation, which contains olive oil,
and an existing lipid-containing artiﬁcial tear prepa-
ration (DET). The efﬁcacy, clinical safety, and accept-
ability of ADV2 was demonstrated in a heterogeneous
group of patients with dry eye (including those with
and without lipid deﬁciency), suggesting that a lipid-
containing artiﬁcial tear such as ADV2 (now com-
mercially available) may be suitable as ﬁrst-line
therapy for dry eye, regardless of etiology.
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